Neoprobe's gamma detection system - CE-marking:
This article was originally published in Clinica
Neoprobe has CE-marked its neo2000 system, a gamma detector designed to pinpoint cancer during surgery. The Dublin, Ohio-based company says it will use the system as a platform for the launch of other intraoperative lymphatic mapping devices later this year.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.